|Group||Author/year of publication||Disease||Study design||Number of individuals||Loss-to-follow-up (%)||Main results|
|Interventions with opioid agonist treatment||Achmad, Y.M. et al (2009)||HIV||Cohort||223||No difference between the intervention group and the control group. No data are available.||
Virological response (HIV viral load): IG: 97 % versus CG: 90 %, p = 0.27|
Immunological response (CD4 cell count): IG: 69 % versus CG: 57 %, p = 0.93.
|Batki, S.L. et al (2002)||TB||RCT||111||52%||TBC completion (≥ 80 % of the doses administrated): 59.5 % in Standard Methadone Treatment, 77.1 % in Minimal Methadone Treatment and 13.1 % in Routine Care, p < 0.01.|
|Bruce, D.R. et al (2012)||HCV||RCT||21||67%||SVR: Six of ten in the intervention group and one of four in the control group, achieved SVR|
|Lucas, G.M. et al (2010)||HIV||RCT||93||17%||HIV RNA and CD4 cell count: No significant differences between opioid agonist therapy in the clinic-based buprenorphine strategy versus specialized opioid treatment program were found (p = 0.31 and p = 0.16, respectively)|
|Morozova, O. et al (2013)||TB||Cohort||110||18 %||Treatment completion: IG: 90 % versus CG: 74 %, p = 0.03.|
|Tetrault, J.M. et al (2012)||HIV||RCT||47||30%||Virological response (HIV viral load): Descreased from 58 % at baseline to 43 % at 12 weeks in IG, and from 56 % to 35 % in CG, p = 0.84 and p = 0.27, respectively.|
|Interventions without opioid agonist treatment||Groessl, E.J. et al (2017)||HCV||RCT||79||37%||SVR: 67 % in IG versus 55 % in CG, p = 0.23.|
|Ho, S.B. et al (2015)||HCV||RCT||363||53%||
SVR: 16 % and 8 % in IG and in CG, respectively, achieved SVR. OR 2.26 (95 % CI: 1.15-4.44, p = 0.02)|
SVR (active substance users and alcohol dependents): IG: 11 % versus CG: 7 %, p = 0.49.
|Sánchez, G.C. et al (2012)||HIV||Cohort||119||In IG 13 % versus in CG 8 % permanently discontinued treatment.||
Virological response (HIV RNA load < 50 copies/mL) at week 48: 93 % (95 % CI = 87 % - 99 %) in IG versus 94 % (95% CI = 84 % - 100 %) in CG.|
Virological response (HIV RNA load < 50 copies/mL) at week 96: 87 % (95 % CI = 79 % - 95 %) in IG, and 88 % (95% CI = 78 % - 97 %) in CG.
No significant differences were found, Kaplan-Meier estimates, log rank test, p =0.965.
|Simoni, J.M. et al (2007)||HIV||RCT||136||All recruited were followed up, but only 59 % at baseline, 65 % at three months, and 61 % at six months reported adherence on 95 % or more.||HIV RNA: HIV suppression was not found significantly different between the integrated group and the control group at baseline, three months and six months follow up.|